Catalyst Pharmaceutical Partners is a specialty pharmaceutical company engaged in developing and commercializing prescription drugs that target orphan neurological diseases and disorders. Firdapse, the company’s lead candidate, is currently undergoing testing in a global, multicenter phase III trial for treating LEMS. Catalyst is also developing a potentially safer and more potent vigabatrin analog for treating infantile spasms, epilepsy and other neurological conditions associated with reduced GABAergic signaling. For more information, visit the company’s Web site: http://www.catalystpharma.com
Let us hear your thoughts below: